T hat susceptibility to type 2 diabetes has a genetic component is well recognized. Linkage studies in large cohorts are underway, but no novel genes have yet been identified (1) . However, the study of rare types of diabetes related to single gene defects has been highly informative in our understanding of the etiopathogenesis of the diabetic condition. For example, in 1997, Stoffers et al. (2) identified a homozygous mutation of insulin promoter factor 1 (IPF-1) as the cause of pancreatic agenesis and recently showed that heterozygosity for an IPF-1 mutation predisposes to early adult-onset type 2 diabetes (3). We have taken this latter approach with a molecular analysis of transient neonatal diabetes (TND). We believe that TND likely results from a single gene defect, and, because it is associated with intrauterine growth retardation and a tendency to develop diabetes later in life, the gene may have relevance to more common types of diabetes. TND is a rare but well-recognized type of diabetes (incidence of 1/400,000) (4). Growth-retarded infants present within the first few days of life with hyperglycemia, dehydration, and minimal ketosis. Endogenous insulin levels are low or undetectable, and exogenous insulin is usually required for a mean duration of 3 months. The condition resolves by 18 months of age, but type 2 diabetes may recur in early adulthood (4, 5) . TND is distinct from classic type 1 diabetes because patients do not carry the common HLA susceptibility haplotypes, and no evidence exists of autoimmune disease (6) .
In 1995, Temple et al. (7) discovered that 2 cases presenting with TND had paternal uniparental isodisomy (UPD) of chromosome 6 (i.e., the inheritance of 2 chromosome homologs from one parent with no contribution from the other). A total of 5 further cases with TND and paternal UPD6 have since been reported in the literature (8) (9) (10) (11) (12) , and another involved a child with diabetes who died at the age of 16 days (13) . The association is now firmly established, although 2 cases of paternal UPD6 have been reported in older patients with no early history of TND, which cannot yet be explained (14, 15) . We and others have subsequently shown that several nondisomic children with TND have paternally inherited duplications within the long arm of chromosome 6 (6q23-24) (12, (16) (17) (18) . Evidence from one of these families suggested that inheritance of an identical duplication from the mother did not lead to TND (16) . This was in keeping with the 18 cases of maternal dupli-cation of the region, which have been described in the literature as without neonatal diabetes (18) , and likewise TND has not been reported in maternal UPD6 (19). One additional case of duplication of 6q and TND has been reported for which the origin of the duplication is unknown (20) .
These observations have led to the hypothesis that overexpression of a paternally expressed allele at 6q24 causes TND with no expression of the maternally inherited allele (16, 21) . A critical region of duplication has been mapped by Gardner et al. (21) and lies within a 400-kb region of 6q24. A differentially methylated CpG island was found within the critical region and was methylated only on the maternally inherited chromosome 6 homolog. All patients with paternal UPD6 showed a complete lack of methylation at the site, as did 2 additional patients with TND and no other chromosome 6 abnormalities. (Only 1 of these had sufficient clinical data for inclusion in this article.) This finding suggested that methylation defects at this locus could be causative and has further strengthened the likelihood that an imprinted gene is involved. Kamiya et al. (22) reported that ZAC/PLAGL1, which is within the critical TND region and is 85 kb from the imprinted CpG island, is imprinted in fetal tissues and is thus a strong candidate gene for TND. The gene for TND is implicated in normal pancreatic function, and its discovery may further our understanding of susceptibility to more common types of diabetes.
We report an analysis of the largest cohort of TND cases studied to date and compare the phenotype with molecular findings at chromosome band 6q24.
RESEARCH DESIGN AND METHODS
Patients. Eligible patients were defined as presenting at >35 weeks of gestation with persistent hyperglycemia within the first 6 weeks of life and recovery by 18 months. The main exclusion criteria were prematurity and persistent diabetes. We recruited patients through the British Paediatric Association Surveillance Unit, clinical geneticists, neonatologists, pediatric endocrinologists, the British Diabetic Association, and authors of TND reports during the last 20 years. All referring clinicians were asked to complete a clinical questionnaire regarding birth history and subsequent progress of the child. Blood samples were requested for cytogenetic and molecular analysis. Genetic investigation. A karyotype was determined when possible for each patient using standard techniques. A modification of the method of Pinkel et al. (23) was used for chromosome painting with a whole-chromosome paint for chromosome 6 (Cambio). DNA was extracted from blood samples of the patients and (when possible) their parents using a salt precipitation method (24) .
To test for uniparental disomy of chromosome 6, the DNA samples were analyzed using polymorphic microsatellite repeats (Généthon or GDB) along the length of chromosome 6 ( Table 1 ). The DNA was amplified in a PerkinElmer (Norwalk, CT) 9600 programmable heating block according to the protocol of Hudson et al. (25) .
Patients who did not have uniparental disomy or a visible duplication of chromosome 6 were analyzed by fluorescent quantitative polymerase chain reaction (PCR) (21, (26) (27) (28) . Eight sets of primers from within the TND critical region were used to amplify nonpolymorphic unique sequences (sequence tagged sites [STSs] or expressed sequence tags [ESTs] ). Primer sequences were obtained from the Sanger Centre's (Cambridge, U.K.) chromosome 6 database (http://www.sanger.ac.uk/hgp/chr6/) and were all located between stSG1437 and stSG27894 (21) (Fig. 1) . These primers and a control primer pair from chromosome 5q21 were manufactured by MWG Biotech. A fluorophore was attached to the 5Ј end of 1 primer in each pair. A total of 100 ng DNA was amplified by multiplexing a primer set from within the TND critical region with the control primer set. Amplification was carried out in a Perkin-Elmer 9600 programmable heating block using the following conditions: 95°C for 15 min followed by 19 cycles of 94°C for 45 s, 52-57°C (depending on the annealing temperature required by a particular primer set) for 45 s, and 72°C for 1 min. This was followed by 7 min at 72°and 1 h at 60°C. A total of 19 cycles were performed to maintain amplification within the linear range. PCR products were separated by polyacrylamide gel electrophoresis using an ABI 377 automated sequencer. The peak height of each allele was quantified using Genotyper software, and the ratio of test:control was calculated to yield a relative measurement of sequence copy number in each individual (Fig. 2) . Control samples with known duplications and without duplications of the region were included in each experiment. Peak height ratio means were calculated for both sets of control subjects along with the 95% CIs and SDs. Ratios obtained from the patient samples fell within the 95% CIs of either the duplicated or control samples. Table 2 shows the results for the proband of each family with a submicroscopic duplication using 1 of the critical markers. Each patient was tested with each marker at least twice in different experiments. This method has been further substantiated as in 8 out of 9 of the submicroscopic duplications that were identified in TND probands, samples from other family members were available, and an identical duplication was demonstrated in 1 or more relatives.
After the identification of a CpG island with a methylation imprint, the methylation status of the patient DNA was determined. DNA was digested with isoschizomers HpaII and MspI before amplification by PCR using primers spanning CCGG sites (21) .
RESULTS
Genotype analysis. We ascertained 30 patients who fulfilled the criteria. Of these, 23 were sporadic cases (including 1 set of identical twins), and 7 were familial (3 from 1 family [29] and 4 from the other [30, 31] ). The clinical and molecular details are shown in Table 3 .
We were able to divide the patients into 4 etiological groups. Group 1 consisted of 11 patients from 10 families (including 1 set of identical twins) ( Table 3 , identification number [ID] 1-11) who were shown to have paternal isodisomy of chromosome 6. In group 2, 11 patients were identified with a duplication of part of chromosome 6q. These included all 7 familial cases (families K and L) and 4 sporadic cases ( (16, 17) , and 9 were identified using quantitative PCR of ESTs and STSs from the region (Fig. 1, ID [12] [13] [14] [15] [16] [17] [18] [19] [20] . Determining the parental origin in 9 of the duplication cases (visible and submicroscopic) was possible by testing both parents using the same method as that used for the probands. In all cases, an identical duplication was demonstrated in the father. In 2 cases (both adults, ID 12 and 20), testing was not possible because parental samples were not available. Group 3 consisted of 1 sporadic patient with a methylation mutation and no other evidence of a chromosome 6 rearrangement. Group 4 (all sporadic cases) consisted of the remaining 7 patients with no identified abnormality of chromosome 6. Phenotype analysis. Clinical findings were compared in the 4 etiological groups.
2 analysis for sex, gestation, birth weight, presentation by 7 days, recovery by 2 months, and subsequent recurrence of diabetes showed no significant differences between the groups (data not shown). boys and girls were approximately equal in the sample group (16 girls, 14 boys), and no consistent pregnancy complications other than intrauterine growth retardation were reported in this cohort. The mean birth weight was 2.1 kg at a mean gestation of 39 weeks. A total of 83% of the patients had a birth weight at or below the 2nd percentile for gestational age.
The placenta was recorded as normal in 2 patients and small
and of gritty consistency in 3 patients, and histological evidence of a rare placental tumor (a choriohemangioma) was reported in patient 8 (Table 3 ). A total of 7 patients had macroglossia, and 2 patients had umbilical hernias. These cases did not derive from any particular etiological group. The median day of presentation was day 3 with a range from a few hours of age to 31 days. ----
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surement was made at the time of diagnosis in 11 cases and was low or negligible in the presence of significant hyperglycemia. Ketones were not present in the urine of all patients tested. Islet cell antibodies were negative in all cases (n = 13). The median duration of exogenous insulin requirement was 12 weeks with a range from 4 to 60 weeks (mean of 16 weeks), and age at recovery coincided with a normalization of growth parameters.
Recurrence of diabetes occurred in 11 of 18 patients >4 years of age. The average age at recurrence was 14 years (range 4-25 years). A total of 8 patients have required treatment with insulin, although in 2 cases, this requirement is intermittent (Table 3, ID 25 and 28) , and the daily requirements in the remainder are less than those usually necessary for type 1 diabetes. Two patients with treated with diet alone, and 1 was treated with a sulfonylurea. The details of treatment are not known for 1 patient. In 3 young cases, intermittent hyperglycemia has been documented during an intercurrent illness (Table 3, ID 8, 26 , and 29), which suggests some disordered pancreatic function. The oldest patient with no evidence of recurrence is 32 years of age. No complications of diabetes are reported in any of the patients. The oldest diabetic patient in this series is 36 years of age and has had diabetes for 16 years.
Growth and development were normal in all but 4 patients, and likely explanations for delays were available for 3 of these patients. One patient (Table 3 , ID 2) has low intelligence, which is consistent with a known abnormal karyotype (47,XXX). Patient 8 (Table 3 ) has a supernumerary chromosome (7) and mild behavioral difficulties noted by 5 years of age. Patient 21 (Table 3 ) presented at 9 days of age with dehydration and collapse at diagnosis. Patient 27 (Table 3) has spastic tetraplegia and profound retardation with no obvious explanation. Puberty has been reported as normal when recorded in all but the 1 patient with 47,XXX in whom puberty occurred prematurely at 9 years of age. Individuals with duplication of 6q have reproduced successfully, but no children have been born to the UPD cases.
Correlations were determined for several variables in the sample. The only significant correlation was between early age at recovery and late age at recurrence of diabetes (r = -0.734, P = 0.016, n = 10) in the 10 patients for whom the analysis was possible. No other obvious correlations and notably no relationship between birth weight and any other variable were evident. Stepwise regression analysis of the data using stratified birth weight and age at recurrence of diabetes as dependent variables did not reveal any further relationships within the data, possibly because of the small sample size. Data are means ± SD (95% CIs), unless otherwise indicated. Peak height ratios for duplicated and nonduplicated control subjects are shown with the result obtained for the proband in the same PCR reaction. The SD and 95% CIs were calculated from the 2 control groups. Patient results were reported as duplicated if the peak height ratio fell within the duplication control CI and nonduplicated if the peak height ratio fell within the nonduplicated control CI. reported by Temple et al. (16) , a paternal cousin of the 3 affected brothers (who had no history of TND) developed gestational diabetes and later diet-controlled type 2 diabetes. She has recently been shown to have inherited a submicroscopic duplication identical to that of her cousins. She inherited this from her asymptomatic father, who is the brother of the probands' father. Patient 19 (Table 4) , who had a submicroscopic duplication of 6q24 inherited from her asymptomatic father, has a brother 25 years of age with early-onset type 2 diabetes. He was diagnosed at the age of 14 years, is treated by diet alone, and has also been shown to have a paternal duplication. A family history of type 2 diabetes was identified in 7 patients. In 5 patients, type 2 diabetes was reported in a maternal grandparent. When analyzed by etiological group, 4 of the possible 16 grandparents from the unknown group (no details were available for 3 families) were identified with type 2 diabetes, which is an incidence of 25%. In each case, type 2 diabetes was inherited through the proband's mother. The incidence of type 2 diabetes in the grandparents in the UPD group is 5%, which approximates the quoted national incidence figures of ~2-5% (34).
Family history. Family history of diabetes is shown in

DISCUSSION
Clinical findings. This study represents the largest cohort of TND patients worldwide and involved an extensive international collaboration (see ACKNOWLEDGMENTS) . Most patients presented during the first week of life and had a birth weight below the 2nd percentile. This is in keeping with previous findings (4, 12, 35) . Insulin therapy was required in all but 1 patient (who was treated by rehydration and monitoring of her blood glucose levels with no obvious adverse effects as previously reported) (7) . In this cohort, recovery occurred by 15 months of age with all but 2 patients recovering by 9 months of age. That the 2 congenital anomalies reported in this and other studies, macroglossia and umbilical hernia, are also reported in Beckwith-Wiedemann syndrome is intriguing because Beckwith-Wiedemann syndrome is known to result from an imprinting error and is associated with hyperinsulinemia. Christian et al. (10) reported macroglossia to be exclusive to patients with UPD6; however, we found macroglossia to be associated with TND in patients with UPD6, paternal duplications of 6q, and those with no known chromosome 6 abnormality. No trend was clear between birth weight and age at presentation, time of remission, or chance of recurrence of diabetes. The one significant correlation suggests that milder TND may be associated with later age at onset of recurrence of diabetes, and we will be interested to see whether this is confirmed by other studies.
All patients were negative for islet cell antibodies when the test was performed, which supports the theory that the etiopathogenesis is not an autoimmune process as seen in classic childhood type 1 diabetes. None of the patients have undergone surgery or died, and therefore no pathological examination of the pancreas has been undertaken. Further evidence indicating that the condition is more akin to type 2 diabetes is the variability of treatment modalities at the time of recurrence of diabetes. The surprisingly low requirement for exogenous insulin, the intermittent nature of the therapy, and the finding of insulin resistance in 2 cases, as discussed by Shield et al. (4) , are also in keeping with type 2 diabetes rather than classic type 1 diabetes. The risk of recurrence of diabetes cannot be determined from a study such as this because of a bias toward ascertainment of patients in whom recurrence has occurred. Subsequent growth, development, and puberty have been normal in all patients except 4, and in 2 of those, a second genetic anomaly (47,XXX and a supernumerary marker chromosome) was discovered. The neurological abnormalities of 1 patient are likely to have resulted from profound dehydration as a result of TND. Genotype/phenotype comparisons. No apparent phenotypic difference was evident among the patients with UPD6, duplication of 6q24, a methylation defect, and no identifiable anomaly of chromosome 6. This lends further support to the hypothesis that the genetic mechanism of TND is similar in most patients (i.e., 2 copies of a paternal allele at 6q24). Other mechanisms causing overexpression of the paternal gene or inappropriate expression of the maternal allele could account for the remaining cases. The additional presence of a maternal allele in the paternal duplication cases appears to have little clinical effect, and, interestingly, no evidence exists that general intellectual development is lower in the duplicated group. Genetic implications. Genetic counseling should be offered to TND patients. Those patients with paternal UPD would be predicted to have a low sibling and offspring risk. All inherited cases in this series have a paternally inherited submicroscopic duplication, which explains familial recurrence and positive linkage to 6q23-q24, as previously reported (16) . Women with the duplication may pass it on, and TND may occur in subsequent generations. Those men with a duplication will have a 50% risk of passing on the duplication and having a child affected by TND. However, these symptoms are not inevitable at birth. This observation follows the paternally transmitted duplication demonstrated in the paternal cousin of the 3 affected siblings (ID [16] [17] [18] and the older brother of patient 19, who had no history of TND but developed diabetes in later life. Both cases suggest that the clinical spectrum associated with submicroscopic 6q duplications may be broader than that in typical TND cases and lends support to the possibility that molecular rearrangements or imprinting anomalies at 6q24 may have implications for more common types of diabetes. In the unknown etiologic group and the methylation defect case, the recurrence risk cannot be predicted. The incidence of type 2 diabetes in the grandparents of the probands in the unknown group is surprisingly high and may indicate a shared susceptibility to diabetes in adult life. Of the 5 patients with a maternal grandparent with type 2 diabetes, 3 are from the unknown etiological group. We theorize that mutation of a maternally inherited imprinting control center within 6q24 could cause inappropriate expression of a maternal allele; a precedent for such a disease mechanism exists in BeckwithWiedemann syndrome mutations on chromosome 11p (36) .
This study identified the cause of TND in 70% of sporadic cases and 100% of familial cases and highlighted the clinical findings in a large cohort of patients. We predict that identification of the gene for TND will yield important insights into early pancreatic development. Low or undetectable insulin levels in TND at presentation with subsequent recovery suggest that the gene product delays the production or release of insulin. Speculating on its role in the low birth weight of TND patients and subsequent development of adult diabetes is tempting. The genes responsible for maturityonset diabetes of the young have been shown by Hattersley et al. (37) to have a similar effect, and the gene for TND may be a further example of a gene with a function in fetal life that plays a role in adult-onset disease.
